HELP YOUR PATIENTS TAKE PART IN RESEARCH FROM HOME
WE MAKE IT EASY FOR ANYONE, ANYWHERE TO PARTICIPATE IN CLINICAL RESEARCH.
Benefits of the Science 37 Study Model
Make it simpler for patients to participate
We accelerate clinical research by making it simple for patients to participate. By engaging with patients from the comfort of their own home, we provide access to patients who can never be reached by the traditional site-based model. In the traditional model, patients must live within the area of the selected sites, and patients must often make their own arrangements for logistics such as time off work, transportation, and childcare. These constraints contribute to why less than 5% of the U.S. population participates in clinical trials. It also means that patients are waiting longer for breakthrough treatments. Virtual trials reduce barriers to participation by bringing the research to the patients in the comfort and convenience of home, which eliminates many of the barriers inherent in the traditional model. Virtual trials also reach and engage broader, more representative, and otherwise inaccessible populations of qualified candidates. We leverage mobile technology and telemedicine to connect participants with the study team—anytime and anywhere—throughout the process.
Stay connected to your patients
Although Science 37 study participants are supported by an expansive network of investigators and home-health nurses across therapeutic areas, we believe that primary care clinicians and other local healthcare providers are an important trusted resource to their patients who are taking part in clinical research. The ability to keep in touch during a study helps to improve the patient experience and ensure that patients are supported. Science 37’s study teams stay connected to participants and are always available to their local clinicians. Select study visits and assessments not appropriate for telemedicine may be conducted at locations within the patient’s local healthcare community whenever possible. From the beginning to the end of study participation, local providers can maintain a relationship with their patients who have joined a Science 37 research study.
Access study staff safely and securely
Our high-touch patient services include patient visits conducted via telemedicine and mobile nurse visits, both at the patient’s convenience. Patients can safely and securely participate in clinical research from the comfort of home through Science 37’s mobile technology platform—the industry’s first and only comprehensive platform purpose-built to execute virtual trials. It supports virtual recruitment, electronic consent, videoconferencing, and seamless data collection, which streamlines remote interactions and data exchange between participants and study teams. The platform not only facilitates accurate, real-time data capture during in-home visits, but also offers patients a direct line of communication with our study teams.
Restless Legs Syndrome Res...
Find a new path forward for adolescent restless legs syndrome through research.
Science 37 Raises $29M To Bring Clinical Trials Directly Into Patients...Series C growth round led by Glynn Capital Management with participation from GV (formerly Google Ventures), along with existing venture and strategic investors
A Potential Solution to More Diversity in Clinical TrialsScience 37's decentralized clinical trial model can reach more patients than traditional sites. This may be an answer to increasing access to new therapies for minorities and also to help ensure patient safety. Healthcare professionals can all help to raise awareness about clinical research.
Science 37 and Sanofi Introduce a New PartnershipWithout clinical trials, new medicine may never make it from the research lab to patients in need. These carefully designed studies can provide important data that include proper dosage, benefit to patients, and potential side effects. There is a growing challenge, however, in finding appropriate participants, especially for treatments that target highly specific conditions affecting narrower patient populations. Right now, there are more than 40,000 clinical studies recruiting patients in the U.S. alone, with some…
Playing for the Long Term – NYT DealBook Conference(Science Launch with Dr. Noah Craft Co-founder and CEO of Science 37 - courtesy of New York Times DealBook Conference) Two weeks ago, I was presented with a great opportunity to speak amongst some very distinguished individuals at the New York Times DealBook Conference. In a modern world of instant gratification, this conference gave some innovators the chance to come together and speak of long term visions or goals. At Science 37, we're combining technology advances that…
Science 37 and LA BioMed launch telemedicine substudy arm of global PE...LA BioMed and Science 37 have launched their first collaborative clinical research trial and enrolled patients in the first-ever virtual, networked clinical trial using telemedicine to monitor the effects of an infusion medication. The research study will compare the effects of rituximab with another medication called mycophenolate mofetil in treating adults with active pemphigus vulgaris (PV). Pemphigus vulgaris is an auto-immune skin condition that causes your skin to form blisters. LA Biomed is one of…